Literature DB >> 6204037

Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis.

F D Boudinot, W J Jusko.   

Abstract

The effects of drug stability, radioactive tracer purity, buffer composition, protein concentration, and fluid shifts on the nonlinear plasma protein binding of prednisolone were examined by equilibrium dialysis. Prednisolone exhibits a concentration-dependent degradation; however, the limited extent of this does not affect protein binding. Impure tritiated prednisolone used as a tracer produces incorrect, low fractional binding values with the binding parameters generated for transcortin affected more than those for albumin. Isotonic sodium phosphate and Krebs original Ringer phosphate buffers yield similar fractional binding of prednisolone and identical protein binding parameters. Fractional binding of the steroid decreases with total plasma protein concentration, but the association constants remain constant over a twofold dilution of plasma proteins. Further dilution increases these parameters. A time-dependent colloidal osmotic fluid shift during dialysis causes dilution of plasma protein concentrations and diminished drug binding. Theoretical simulations show that the osmotic fluid shifts produce the largest changes in fractional binding for compounds that are bound by low-capacity proteins with low association constants (K less than 10(6) M-1). A mathematical equation was developed to correct bound drug concentrations and fraction bound for protein dilution caused by this effect. The fluid shifts can be prevented by the addition of dextran (mol. wt. 70,000) to the dialysis buffer in a concentration of 55% of the total protein concentration. Multiple factors can diminish the nonlinear prednisolone binding as artifacts during equilibrium dialysis, but the changes are relatively modest.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204037     DOI: 10.1002/jps.2600730617

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  29 in total

1.  The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.

Authors:  G Everson; K C Lasseter; K E Anderson; L A Bauer; R L Carithens; K D Wilner; A Johnson; R J Anziano; T A Smolarek; R Z Turncliff
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

2.  Development of a whole body physiologically based model to characterise the pharmacokinetics of benzodiazepines. 1: Estimation of rat tissue-plasma partition ratios.

Authors:  Ivelina Gueorguieva; Ivan A Nestorov; Susan Murby; Sophie Gisbert; Brent Collins; Kelly Dickens; Judith Duffy; Ziad Hussain; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

3.  Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal.

Authors:  Leonid M Berezhkovskiy
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-07-14       Impact factor: 2.745

4.  Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Authors:  Michael A Mohutsky; Jenny Y Chien; Barbara J Ring; Steven A Wrighton
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

5.  Single and multiple dose pharmacokinetics of tenidap sodium in healthy subjects.

Authors:  M J Gardner; K D Wilner; R A Hansen; H G Fouda; G F McMahon
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

6.  A modified equilibrium dialysis technique for measuring plasma protein binding: experimental evaluation with diazepam and nortriptyline.

Authors:  H H Chow; S P Khor; H C Lee; M Mayersohn
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

Review 7.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

8.  Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy.

Authors:  Hua Lv; Xiaoping Zhang; Jyoti Sharma; M V Ramana Reddy; E Premkumar Reddy; James M Gallo
Journal:  AAPS J       Date:  2012-11-22       Impact factor: 4.009

9.  Kinetic assessment of apparent facilitation by albumin of cellular uptake of unbound ligands.

Authors:  D J Morgan; C K Stead; R A Smallwood
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

10.  Pharmacokinetics of antiviral polyoxometalates in rats.

Authors:  L Ni; F D Boudinot; S G Boudinot; G W Henson; G E Bossard; S A Martellucci; P W Ash; S P Fricker; M C Darkes; B R Theobald
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.